Details for 2018829880
Up to date per 01.04.2026
Actions
Details for 2018829880
Granted/Registered
European Patent
28.10.2020 A
24.01.2024 B1
21.12.2017
EP
17382884
G01N 33/574 20060101AFI20230511BHEP
Owner
Fundació Privada Institut d'Investigació Oncològica de Vall-HebronNatzaret, 115-117 Edifici Cellex 08035 BarcelonaES
AstraZeneca UK Limited1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 0REGB
XenTech SASGenopole Campus 3 4 Rue Pierre Fontaine 91000 EvryFR
Representative
Representative
Schwarz & Partner Patentanwälte GmbHWipplingerstraße 301010 WienAT
Inventor
SERRA ELIZALDE, VioletaCarrer Rosari, 19 08340 Vilassar de Mar, BarcelonaES
BALMAÑA GELPI, JudithCarrer de Bori i Fontestà, 7, 7º, 2ª 08021 BarcelonaES
CRUZ ZAMBRANO, CristinaCarrer Sant Jordi, 5 08338 Premià de Dalt, BarcelonaES
LLOP GUEVARA, AlbaCarrer Montserrat, 38 08172 Sant Cugat del Vallès, BarcelonaES
CASTROVIEJO BERMEJO, MartaAvenida Portugal, 1 2 Izq. 26001 LogroñoES
O'CONNOR, Mark J.ASTRAZENECA UK LIMITED 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 OREGB
JONES, Gemma NicoleASTRAZENECA UK LIMITED HODGKIN B900 Chesterford Research Park Little Chesterford Cambridgeshire CB10 1XLGB
Information about Fees